|Videos|November 30, 2017 (Updated: October 7, 2020)

Choosing Between TAS-102 and Regorafenib in Colorectal Cancer

Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses choosing between TAS-102 (Lonsurf) and regorafenib (Stivarga) in colorectal cancer.


Latest CME